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The functional association of NPM1 with Aurora kinases is well documented. Surprisingly, although
NPM1 is a well characterized phosphoprotein, it is unknown whether it is a substrate of Aurora
kinases. We have found that Aurora kinases A and B can phosphorylate NPM1 at a single serine
residue, Ser125, in vitro and in vivo. Phosphorylated-S125-NPM1 (pS125-NPM1) localizes to the
midbody region during late cytokinesis where it colocalizes with Aurora B. The overexpression of
mutant (S125A) NPM1 resulted in the deregulation of centrosome duplication and mitotic defects
possibly due to cytokinesis failure. Thesedata suggest thatAurorakinaseB-mediatedphosphorylation
of NPM1 plays a critical role during mitosis, which could have wider implications in oncogenesis.
Structured summary of protein interactions:
Aurora A phosphorylates NPM by protein kinase assay (1, 2)
Aurora B phosphorylates NPM by protein kinase assay (View interaction)
NPM and Aurora A colocalize by ﬂuorescence microscopy (View interaction)
NPM and Aurora B colocalize by ﬂuorescence microscopy (View interaction)
NPM binds to Aurora B by pull down (View interaction)
NPM physically interacts with Aurora B by anti tag coimmunoprecipitation (1, 2)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
NPM1 is a highly dynamic nucleolar protein that plays an
important role in diverse cellular processes such as ribosome
biogenesis [1], centrosome duplication [2,3], the maintenance of
genomic stability and embryonic development [4]. It possesses
intrinsic histone chaperone activity [5], which allows it to regulate
RNA polymerase I [6] and RNA polymerase II-dependent transcrip-
tion [7]. NPM1 undergoes a variety of post-translational modiﬁca-
tions, such as phosphorylation, acetylation and sumoylation, that
regulate its subcellular localization and functions [6,8]. NPM1 isphosphorylated by various kinases during different stages of the
cell cycle [6]. NPM1 associates with unduplicated centrosomes,
but upon phosphorylation at Thr199 by CDK2/cyclin E at the onset
of mitosis, it dissociates from the centrosome, leading to
centrosome duplication [9]. Aurora kinases A and B belong to the
family of serine/threonine kinases whose activity and expression
peak during mitosis. Aurora A is involved in centrosome
maturation, duplication and spindle organization, whereas Aurora
B is mainly involved in chromosomal condensation, alignment,
segregation and proper cytokinesis [10]. An ever-expanding list
of Aurora A and B substrates has been reported thus far; most of
these substrates are involved in the mitotic phase of the cell cycle.
The majority of substrates enhance the activity of Aurora kinases
by inducing autophosphorylation. Recently, it has been shown that
NPM1 enhances the autophosphorylation of Aurora kinase A in the
centrosome [11]. In this report, we found that NPM1 is a novel
substrate of Aurora kinases A and B that is phosphorylated at the
same site, Ser125, by both kinases. Small interfering RNA
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A and B maintain cellular levels of phosphorylated-S125-NPM1.
Remarkably, the overexpression of phosphorylation-defective
mutant (S125A) NPM1 in cells leads to an aberrant increase in cen-
trosome number and distinct mitotic defects.
2. Materials and methods
2.1. Plasmid constructs
His6-tagged full length NPM1 and deletion mutant constructs
NPM1 (1–200), NPM1 (1–147) and NPM1 (1–119) have been
described earlier [7]. The His6-tagged deletion mutant constructs
NPM1 (D120–126) and (D120–132) and GST-tagged NPM1
constructs have been described in [12]. The point mutants S125A
and S125E mutants generated by site-directed mutagenesis
(Stratagene) were subcloned into pCMV-FLAG mammalian expres-
sion vector (Sigma), between the Xba I/Hind III restriction sites
resulting in N-terminal FLAG tagged constructs.
2.2. In vitro assays
Kinase assays were performed as described in [13]. GST
pulldown assays were performed as described in [12].
2.3. Site-directed mutagenesis
Point mutations of NPM1 were generated using the site-direc-
ted mutagenesis kit (Stratagene), according to the manufacturer’s
instructions.
2.4. Antibodies, inhibitors and immunoﬂuorescence
Polyclonal antibodies in rabbits were raised against a phospho-
peptide (residues 120–129 of NPMI) conjugated with Keyhole
Limpet (KLH) (Peptron) (EEDAE[SPO4]EDEE-C-KLH) following the
standard regimen of priming and booster doses for antibody
generation.
Aurora A and Aurora B antibodies used in immunoﬂuorescence
analyses were purchased from BD Biosciences. Aurora B antibody
used for Western blotting analysis and immunohistochemistry
analyses was purchased from Merck Millipore. a-Tubulin antibody
was purchased from Merck Millipore. c-Tubulin and anti-FLAG
antibodies were from Sigma. pT288 Aurora A and pS10 Histone
H3 antibodies were purchased from Abcam. Puriﬁed anti-pS125-
NPM1 antibody was used for immunoﬂuorescence analysis. In
house-generated anti-NPM1 monoclonal antibody (Clone 28M1)
was used for detecting NPM1. Fluorescently labeled anti-mouse
Alexa 633- and anti-rabbit Alexa 488-conjugated antibodies (Invit-
rogen) were used as secondary antibodies.
Inhibitors MLN8237 and ZM447439 were purchased from
Selleckchem.
Immunoﬂuorescence assays were performed in HEK293T and
NIH 3T3 cells as described in [8].
2.5. Cell culture
HEK293 and NIH3T3 cells were grown in DMEM (Sigma)
containing 10% FBS (Gibco). HEK293 cells were synchronized in
mitotic phase using a thymidine–nocodazole block as described
in [14].
For inhibitor treatment, HEK 293 cells were arrested with
100 ng/mL nocodazole for 24 h and subsequently treated with
the indicated drug in the presence of nocodazole for the ﬁnal 1 h
before harvesting.For silencing experiments, HEK293 cells were transfected for
60 h with scrambled RNA (Sigma) or indicated siRNA using
Hi-Perfect transfection reagent (Qiagen), according to the manu-
facturer’s instructions. After 36 h of siRNA transfection, the cells
were arrested in mitosis in the presence of 100 ng/mL nocodazole
for 24 h, harvested and used for either RNA extraction or whole cell
lysate preparation. The different siRNAs (Dharmacon) used for
knockdown experiments are detailed in Supplemental methods.
NPM1 siRNA was used as described previously [8].
2.6. Immunohistochemistry
Tissue Microarray (TMA) was prepared from 20 oral squamous
cell carcinoma samples along with its normal counterpart by
punching 1 mm core region from the donor blocks. 5 lm parafﬁn
sections were cut for immunohistochemistry for the above
mentioned proteins. Firstly, baking was done for overnight on
dry bath at 56 C and 1 h at 60 C. Sections were subjected to
antigen retrieval in sodium citrate buffer (pH 7.2) for 20 min and
cooled down to room temperature (RT) for further processing.
Sections were blocked in 5% skimmed milk solution for 2 h at RT.
Primary antibodies were then added and kept in humid chamber
for overnight incubation at RT. Slides were developed using
Streptavidin–avidin biotin kit (Dako Inc) and diaminobezidine as
substrate and counterstained by diluted haematoxylin. Slides were
mounted with DPX. Semi-quantitative staining analysis was done
by H-score by counting 400 cells from three different ﬁelds in
the slides considering low, moderate and higher intensity of
protein expression. Nuclear positivity was considered for all the
three proteins. H-score of each protein varies from 0 to 300.
Mann–Whitney U Test was performed for comparing the pS125-
NPM1 expression in normal and cancerous samples. Spearman’s
correlation was done to ﬁnd out the correlation between Aurora
B kinase and pS125-NPM1 protein levels in the same set of oral
cancer samples. Statistical signiﬁcance was considered when P
value is less than 0.05.
3. Results and discussion
3.1. Aurora kinases A and B phosphorylate NPM1 at Ser125
We were interested in determining whether NPM1 could be a
substrate of Aurora kinases. The activities of baculo-expressed
His6-tagged Aurora kinases A and B (Supplemental Fig. S1A, left
and right panels) were assayed, using histone H3 as a substrate
(Fig. S1B, left and right panels). We found that both Aurora A and
Aurora B could phosphorylate NPM1 in vitro (Fig. 1A, left and right
panels). Further, we found that NPM1 interacts with Aurora B but
not with Aurora A in vitro by performing GST pull down assay
(Fig. 1B, compare lane 3 of left and right panels). Immunoprecipi-
tation experiments showed that in cells, Aurora B but not Aurora
A was associated with NPM1 (Fig. S1C, compare lane 3 of panels
I and II) and NPM1 was present in the phosphorylated form
(Fig. S1C, lane 3 of panel III). Using a reverse co-immunoprecipita-
tion approach, we conﬁrmed that indeed NPM1 was associated
with Aurora B in cells (Fig. S1D, lane 4 of panel I). Subsequently,
in vitro kinase assays with C-terminal deletion mutants of NPM1
(Fig. 1C) using Aurora A and B revealed that the phosphorylation
of NPM1 deletion mutant (1–119) was almost completely
abolished, while the other deletions mutants of NPM1 (1–200
and 1–147) were as efﬁciently phosphorylated as the full length
(FL) NPM1 (Fig. 1D, left and right panel respectively). These data
indicated that the probable phosphorylation site resided between
amino acid residues 120–147 of NPM1 (Fig. S2A) which contains
four serine residues (S125, S137, S139 and S143). We made use
Fig. 1. NPM1 is a substrate of Aurora kinases A and B in vitro. (A) In vitro kinase assay performed with 40 ng of Aurora kinases A (left panel) and B (right panel) using 1 lg
His6-NPM1 as substrate in presence (lane 3) or absence of [c-32P] ATP (lane 2). Lane 1 is in absence of Aurora kinases. (B) In vitro GST pull down assay performed with 1 lg of
GST alone (lane 2 of both panels) or GST-tagged NPM1 (lane 3 of both panels) and 200 ng of either Aurora A (left panel) or Aurora B (right panel) proteins. Input is 25% of that
used for interaction. (C) Schematic representation of full length (FL) NPM1 and its deletion mutants. (D) Kinase assay performed with the deletion mutants using either
Aurora A (left panel) or Aurora B (right panel) in presence (lanes 1–4) or absence of [c-32P] ATP (lanes 5–8). (E) Kinase assay performed with wild type (WT) NPM1, NPM1
point mutants: S125A, S125E and T199A with either Aurora A (lanes 1–8) or Aurora B kinase (lanes 9–16) in presence (lanes 5–8 and lanes 13–16) or absence of [c-32P] ATP
(lanes 1–4 and lanes 9–12).
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(Fig. S2B) to identify the precise residues being phosphorylated
by Aurora Kinases. Neither of the deletion mutants was phosphor-
ylated compared to FL NPM1 (Fig. S2C). Since the mutants lack only
a single serine residue, Ser125, we hypothesized that this could be
the probable site targeted by Aurora kinases. We further generated
point mutants of NPM1 where Ser125 was mutated to Ala
(phosphorylation-defective mutant, S125A) and to Glu (phosphor-
ylation-mimicking mutant, S125E). In addition Thr199 of NPM1
was mutated to Ala (T199A) for comparative studies. Subsequently,
in vitro kinase assays performed with these mutants showed that
mutation of Ser125 to either Ala or Glu led to complete abolish-
ment of NPM1 phosphorylation by Aurora kinases (Fig. 1E, lanes
6–7 and lanes 14–15, respectively). These data show that Aurora
kinases A and B phosphorylate NPM1 at Ser125 in vitro.
NPM1 also functions as a histone chaperone, where it interacts
with core histones and mediates their assembly or disassembly
during various cellular processes. To study whether the mutation
of Ser125 alters its ability to associate with core histones, in vitro
interaction assays were performed. We found that the S125A,
S125E, and T199A-NPM1 associated with core histones with
afﬁnities comparable to the WT NPM1 (Fig. S2D). Our data demon-
strated that Aurora kinases phosphorylate NPM1 at Ser125 in vitro.
An earlier report showed that Ser125 is also a target for casein
kinase II (CKII)-mediated phosphorylation [15], which was
conﬁrmed in our kinase assays using CKII (Fig. S2E). CKII phosphor-
ylates NPM1 during interphase and regulates its nucleolarretention and ribosome biogenesis function, whereas the activity
and expression of Aurora kinases A and B peak during the G2/M
phase of the cell cycle. Most likely, the phosphorylation status of
NPM1 at Ser125 during various stages of the cell cycle would be
maintained by these events. Aurora kinases regulate the key events
of mitotic progression, where Aurora A and B have distinct localiza-
tions and functions during mitosis. Hence, it was important to
study the cellular localization of phosphorylated Ser125-NPM1
(pS125-NPM1) during different stages of the cell cycle.
3.2. pS125-NPM1 has a distinct localization pattern during the cell
cycle
We generated polyclonal antibodies against pS125-NPM1 as
described in Experimental Procedures. The anti-pS125-NPM1 anti-
body recognized a speciﬁc band in HEK293 whole cell extracts
(Fig. 2A). In order to demonstrate the speciﬁcity of the antibody,
we knocked down NPM1 expression using speciﬁc siRNA in
HEK293 cells and performed Western blotting analysis with
pS125-NPM1 and NPM1 antibodies. The results clearly demon-
strate that both NPM1 and pS125-NPM1 levels decrease in siRNA
treated cells compared to scrambled RNA control lane (Fig. 2B, lane
2 versus lane 1). To study the differential levels of pS125-NPM1
during and after mitosis, we arrested cells in mitotic phase by a
thymidine–nocodazole block followed by release for different time
points. We observed a decrease in pS125-NPM1 levels at 2 and 6 h
after release which increases at 10 h, followed by a decrease at 14 h
Fig. 2. pS125-NPM1 localizes in the midbody region during cytokinesis. (A) Western blotting analysis of HEK293 cell lysate performed with anti-pS125-NPM1 antibody. (B)
Western blotting analysis performed 48 h post-transfection in asynchronous cells with either scrambled RNA (lane 1) or NPM1 speciﬁc siRNA (lane 2) was done with anti-
pS125-NPM1 (upper panel) and anti-NPM1 (middle panel). (C) Western blotting analysis with asynchronous cells (lane 1), cells synchronized in mitosis (lane 2), and released
for different time points as indicated (lanes 3–6) was performed using anti-pS125-NPM1 and anti-NPM1 antibodies. Western blotting analysis with mitotic markers Aurora
Kinase A and phospho-S10-H3 antibodies show efﬁciency of synchronization. Histone H3 serves as loading control for C and a-tubulin serves as loading control for B and C.
(D) Immunoﬂuorescence image of different stages of the cell cycle using anti-pS125-NPM1 (green) and anti-NPM1 (red).
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levels of mitotic markers Aurora Kinase A and H3 S10
phosphorylation increased at mitosis and decreased after release
from nocodazole block as expected (Fig. 2C). Subsequently,
immunoﬂuorescence analysis was carried out to study the cellular
distribution of pS125-NPM1 and NPM1. The studies illustrated that
pS125-NPM1 is localized as punctate spots in the nucleoplasm and
is excluded from the nucleolus in interphase cells (panel I, Fig. 2D).
It seemed to localize at distinct regions during prophase but did
not colocalize with NPM1 (panel II, Fig. 2D). At the metaphase
stage, pS125-NPM1 was distributed in the cytoplasm and at the
poles, whereas NPM1 was predominantly cytoplasmic (panel III,
Fig. 2D). In the anaphase stage, there were considerably reduced
levels of NPM1 and pS125-NPM1 (panel IV, Fig. 2D). Interestingly,
in the telophase stage, pS125-NPM1 was found to accumulate at
the mid-zone of the segregating cells (panel V, Fig. 2D). At the late
telophase stage, when the cells were on the verge of completing
cytokinesis, there was an almost complete accumulation of
pS125-NPM1 at the mid-zone (panel VI, Fig. 2D). NPM1 staining
was observed throughout the cytoplasm and in the pre-nucleolar
bodies of such cells. To further conﬁrm that the pS125-NPM1 anti-
body speciﬁcally recognizes only phosphorylated form of NPM1,
we performed immunoﬂuorescence imaging using the pS125
NPM1 and NPM1 antibodies in an inducible stable NPM1 knock-
down cell line which was either left untreated or treated with
doxycycline for NPM1 shRNA expression (Fig. S3A). The resultsshow that upon NPM1 knockdown, the pS125 NPM1 staining is
reduced (Fig. S3A–C) clearly demonstrating that the pS125 NPM1
antibody indeed is speciﬁc to NPM1 phosphorylation. The
localization pattern of pS125-NPM1 during cytokinesis is
reminiscent of Aurora B distribution, and hence they could have
overlapping functions at this stage of cell division.
3.3. pS125-NPM1 colocalizes with Aurora B during the late telophase
stage
To further conﬁrm that Aurora A and B kinases phosphorylate
NPM1 in cells, we performed siRNA-mediated knockdown of CKII,
Aurora A and Aurora B in different combinations. The knockdowns
were conﬁrmed by qRT-PCR analysis (Fig. S4A–C). The knockdown
of these kinases did not alter the levels of NPM1 mRNA (Fig. S4D–
F). Depleting any of these kinases alone (either Aurora A, Aurora B
or CKII) did not result in the complete inhibition of phosphoryla-
tion at Ser125 (Fig. S5A). Hence, a combination of siRNAs were
used against either CKII + Aurora A, CKII + Aurora B or CKII + Aurora
A + Aurora B. Western blotting analysis was performed using the
siRNA-treated cells to determine the effect on pS125-NPM1.
Depleting Aurora B + CKII resulted in a signiﬁcant reduction in
pS125-NPM1 levels; a similar effect was observed in the
CKII + Aurora A + Aurora B-depleted cells, while CKII + Aurora
A-depletion led to marginal decrease in pS125-NPM1 levels
(Fig. 3A, compare lanes 2–4 with lane 1). Additionally, no
Fig. 3. Aurora kinase B phosphorylates NPM1 during mitosis and colocalizes with pS125-NPM1 during telophase. (A) Western blotting analysis of cells treated with indicated
combination of siRNAs and arrested in mitosis was done with anti-pS125-NPM1 antibody. Western blotting analysis with anti-NPM1, anti-tubulin antibodies show the
corresponding loading control and anti-Aurora A, anti-Aurora B and anti-CK II alpha antibodies show the efﬁciency of the kinase knockdowns. (B) Western blotting analysis
post-treatment of cells with either DMSO or 1 lM of MLN8237 or ZM447439 in nocodazole arrested cells, using anti-pS125-NPM1 top panel), anti-NPM1 (middle panel) and
anti-tubulin antibodies (bottom panel). (C) Staining of Aurora A (red) with anti-pS125-NPM1 (green) in metaphase stage of the cell cycle and (D) Aurora B (red) with anti-
pS125-NPM1 (green) in late telophase stage. Nuclei were stained using Hoechst (blue). Scale bar is 5 lm.
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Thr199-NPM1 as a consequence of silencing Aurora kinases and
CKII (data not shown). To further establish the enzyme speciﬁcity
for the phosphorylation of NPM1 at Ser125, HEK293 cells arrested
in mitosis were treated with either Aurora A or B-speciﬁc inhibi-
tors, MLN8237 [16] or ZM447439 [17], respectively and Western
blotting analysis was performed using anti-pS125-NPM1 antibody.
We found a modest decrease in pS125-NPM1 levels upon Aurora
Kinase A inhibition (Fig. 3B, compare lanes 2 versus 1), whereas
Aurora Kinase B inhibition led to a signiﬁcant decrease in pS125-
NPM1 levels (Fig. 3B, compare lanes 3 versus 1). We further
checked the speciﬁcity of these inhibitors for Aurora A and Aurora
B respectively by performing an immunoﬂuorescence analysis
using anti-pT288-Aurora A and anti-phsosphoS10-H3 antibodies
(Fig. S6). We found that upon treatment with Aurora A speciﬁc
inhibitor, MLN8237, the phospho-T288 Aurora A signal decreases
but Aurora B speciﬁc inhibitor, ZM447439, does not have any effect
on Aurora A auto-phosphorylation. Treatment with MLN8237
induces a G2/M arrest due to Aurora A inhibition [16] and very
few cells were observed to be in metaphase as is evident fromthe Hoechst staining and the phospho-H3S10 antibody staining.
ZM447439 treatment leads to a reduction in phospho-H3S10
staining which is a well-established substrate for Aurora B kinase
(Fig. S6). The results clearly demonstrate that both the inhibitors
are highly speciﬁc and target the respective kinases in the cell.
Collectively, these results suggest that Aurora B is the bona ﬁde
kinase for NPM1 in the cellular system. To identify the possible
phosphatase for this site, we treated the cells with inhibitors
against protein phosphatase type 1 (PP1) and type 2A (PP2A). Oka-
daic acid at 1 nM concentration inhibits PP2A, while calyculin A
at 2 nM inhibits both PP1 and PP2A [15]. We found a signiﬁcant
increase in pS125-NPM1 levels upon treatment with 5 nM
calyculin when compared to 5 nM okadaic acid treatment
(Fig. S5B, compare lanes 3 and 2 with lane 1), suggesting that
PP1 could be the major phosphatase for pS125. Hence, the activity
and expression of Aurora kinases, CKII and protein phosphatase
type 1 would, in combination, regulate the phosphorylation status
of pS125-NPM1.
Furthermore, co-immunoﬂuorescence analysis was performed
to study the cell-cycle stage-speciﬁc association of pS125-NPM1
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co-localized with Aurora A from the prophase to metaphase stages
(Fig. 3C), whereas it distinctly co-localized with Aurora B speciﬁ-
cally during the late telophase stage (Fig. 3D). The co-localization
pattern of NPM1 along with Aurora B observed at late telophase
indicates the probable role of NPM1 during cytokinesis. Taken
together, these results show that pS125-NPM1 associates with
Aurora kinase B during the telophase and cytokinesis stages.
3.4. Overexpression of FLAG-tagged S125A NPM1 results in centrosome
ampliﬁcation
NPM1 associates with the unduplicated centrosome, but
dissociates upon phosphorylation at Thr199 at the onset of mitosis,
which allows centrosome duplication. The role of pS125-NPM1 in
centrosome duplication is unknown. To address this issue, colocal-
ization studies were carried out using antibodies against c-tubulin
(a centrosomal marker) and pS125-NPM1. pS125-NPM1 did not
associate with the early or late stages of centrosome duplication
(Fig. S7A). To study the functional signiﬁcance of pS125-NPM1 in
centrosome duplication, FLAG-tagged S125A and S125E mutants
of NPM1 were generated. These mutations did not alter the nucle-
olar localization of NPM1 (Fig. S7B). To study the role of pS125-
NPM1 in centrosome duplication, transient transfections withFig. 4. Overexpression of phospho-defective mutant S125A-NPM1 leads to centrosome a
tagged WT NPM1, (B) S125A NPM1 and (C) S125E NPM1 using anti-FLAG (red). Centroso
done with Hoechst. The co-immunoﬂuorescence image is shown in merge. Scale bar is 5
cells with transfection of different constructs as indicated. A minimum of 150 cells per tra
more than or equal to 3 centrosomes in HEK 293 cells with transfection of different const
means ± standard deviation of three independent experiments. The results were evaluatFLAG-tagged WT, S125A and S125E NPM1 were performed in
NIH 3T3 cells followed by immunoﬂuorescence analysis. The
overexpression of WT NPM1 did not lead to any effect on centro-
some duplication, as cells having one and two centrosomes were
predominantly observed (Fig. 4A). However, the overexpression
of S125A-NPM1, led to an abnormal increase in centrosome
number and distinct mitotic defects (Fig. 4B). Many bi-nucleate
cells with three or four centrosomes were observed, indicating a
possible defect in cytokinesis. Interestingly, most of the cells over-
expressing the S125E-NPM1 did not exhibit such abnormalities in
centrosome number (Fig. 4C). Similar results were obtained in
HEK293 cells, where we found that approximately 0–0.6% of empty
vector, FLAG-WT and S125E-NPM1-transfected cells were bi- or
multi-nucleate in nature whereas about 5% of the FLAG S125A-
NPM1 transfected cells were bi- or multi-nucleate (Fig. 4D).
Further, we quantiﬁed the number of cells containing abnormal
number of centrosomes and we found that about 3% of the empty
vector, FLAG-WT and S125E-NPM1 transfected cells had three or
more centrosomes. In contrast, upon FLAG S125A-NPM1 transfec-
tion, this number increased signiﬁcantly to about 13% (Fig. 4E).
Earlier reports showed that overexpression of either T199A or
S4A NPM1 suppressed centrosome duplication and resulted in cells
having predominantly single centrosomes [9,18,19]. However, we
have observed that the overexpression of S125A-NPM1 resultedmpliﬁcation. (A) Immunoﬂuorescence image of NIH 3T3 cells transfected with FLAG
mes (arrows) were visualized using anti-c-tubulin (green). DNA staining (blue) was
lm. (D) Histogram showing the percentage of bi or multi-nucleate cells in HEK 293
nsfection were counted. (E) Histogram showing the percentage of cells with 1, 2 and
ructs as indicated. A minimum of 150 cells per transfection were counted. Values are
ed using student’s t test (⁄⁄P < 0.01).
Fig. 5. pS125-NPM1 levels are high in oral squamous cell carcinoma and correlates well with Aurora B overexpression. (A) Representative images of expression levels of
NPM1, pS125-NPM1 and Aurora B using immunohistochemistry analysis on tissue microarray of oral squamous cell carcinoma tissues. (B) pS125-NPM1 expression levels in
oral tumor and adjacent normal tissues measured by H-score. Data were analyzed by student’s t-test. ⁄⁄P < 0.01, n = 20. (C) Spearman’s correlation co-efﬁcient value = 0.909
shows correlation between Aurora B and pS125-NPM1 expression in tumor samples. ⁄⁄⁄P < 0.0001, n = 20.
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somes could be a consequence of deregulated centrosome duplica-
tion or an indirect effect of cytokinesis failure.
NPM1 has overlapping functions with Aurora kinases, particu-
larly in centrosome duplication and cytokinesis. An earlier report
[4] showed that knockout of NPM1 results in unrestricted centro-
some duplication; and centrosome ampliﬁcation is known to be a
major factor causing genomic instability and aneuploidy in tumor
cells. Our ﬁndings are further supported by another study in which
NPM1 was detected in the Aurora B-complex during cytokinesis
[20]. Aurora A normally acts upstream of Aurora B and is essential
for progression through mitosis; evidence indicates that the
inactivation of Aurora B function bypasses the normal requirement
for Aurora A in mitosis. Aurora B is critically required for the com-
pletion of cytokinesis; knockdown of Aurora B alone or with Aurora
A results in cytokinesis failure, which indirectly leads to centro-
some ampliﬁcation and polyploidy [21]. A similar effect was
observed upon the overexpression of S125A-NPM1. While our
manuscript was under preparation, another study reported that
NPM1 activates Aurora A kinase at the centrosome by enhancing
its autophosphorylation at Ser89 [11]. Most likely, Aurora A and
B-mediated phosphorylation of NPM1 at Ser125 would be essential
for the maintenance of proper centrosome numbers and cytokine-
sis. Aurora kinases are known to be involved in several cancers,
where overexpression and loss-of-function mutations result in var-
ious mitotic defects leading to aneuploidy associated with onco-
genesis [10,22]. Similarly, NPM1 is overexpressed in various
types of solid tumors and might function as an oncogene [8,23].
We have found pS125-NPM1 levels to be high in oral tumor sam-
ples compared to their adjacent normal counterpart (Fig. 5B). We
have also validated the overexpression of Aurora Kinase B and
NPM1 in oral squamous cell carcinoma [8,24,25] in the same
patient samples where pS125-NPM1 levels were high (Fig. 5A).
Further, the overexpression of Aurora B correlated well with the
upregulation of pS125-NPM1 in individual patient oral tumor tis-
sue samples with a Spearman’s correlation co-efﬁcient of 0.9 and
a P-value of 0.0001 (Fig. 5C). The combined effect of overexpression
of Aurora kinases and their substrate NPM1 may play an importantrole in facilitating cancer progression. Collectively, these data
indicate the pathophysiological implications of Aurora Kinase
mediated phosphorylation of NPM1.
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